Due to their cost, however, coverage of GLP-1s for obesity treatment in Medicaid, ACA Marketplace plans, and most large employer firms remains limited, and GLP-1 coverage in Medicare for treatment of obesity is prohibited under current law
From $49/mo Personalized Tirzepatide 2.5mg/week weekly
Potential benefits may warrant use in pregnant women despite potential risks.DThere is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans
Selianitis D, Sentoukas T, Skandalis A, Balafouti A, Pippa N, Pispas S
Patients can use HSA or FSA funds to pay for their medication, and PlexusDx compounds all medications in licensed 503A pharmacies, ensuring pharmaceutical-grade quality and consistency